Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of peptide-prolyl isomerase and calcineurin activity.

abstract：PURPOSE:To investigate the effects of genetic polymorphisms on morphine-induced adverse events in cancer patients. METHODS:We examined the relation of morphine-related adverse events to polymorphisms in UDP-glucuronosyltransferase (UGT) 2B7, ATP-binding cassette, sub-family B, number 1 (ABCB1), and μ-opioid receptor 1...

journal_title：Cancer chemotherapy and pharmacology

authors： Fujita K,Ando Y,Yamamoto W,Miya T,Endo H,Sunakawa Y,Araki K,Kodama K,Nagashima F,Ichikawa W,Narabayashi M,Akiyama Y,Kawara K,Shiomi M,Ogata H,Iwasa H,Okazaki Y,Hirose T,Sasaki Y

更新日期：2010-01-01 00:00:00

abstract：:When tumor cell density increases, the cytotoxic activity of certain anticancer agents, such as vincristine (VCR) and doxorubicin (DXR), progressively decreases. This phenomenon is termed the inoculum effect. Since VCR and DXR are less active in an acidic environment, we questioned whether the inoculum effects could h...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi H,Takemura Y,Ohnuma T

更新日期：1992-01-01 00:00:00

abstract：:3-Deazaguanine (3-DG), a purine analogue, has unusual antitumor activity against experimental mammary tumor models and a number of other solid tumors. Others have shown that mutant CHO cells deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRTase) or adenine phosphoribosyl transferase (APRTase) are resi...

journal_title：Cancer chemotherapy and pharmacology

authors： Singh G,Luna MK,Ardalan B

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver. This regimen was based on our studies with carcinoid cell lines that showed synergistic cytotoxicity with sequence-specific dosing of 5-fluorouracil preceding tem...

journal_title：Cancer chemotherapy and pharmacology

authors： Fine RL,Gulati AP,Krantz BA,Moss RA,Schreibman S,Tsushima DA,Mowatt KB,Dinnen RD,Mao Y,Stevens PD,Schrope B,Allendorf J,Lee JA,Sherman WH,Chabot JA

更新日期：2013-03-01 00:00:00

abstract：PURPOSE:Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFRα. Olaratumab plus doxorubicin improved survivalversus doxorubicin in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised the olaratumab exposure-response relationship for progression-free survival (PFS), ove...

journal_title：Cancer chemotherapy and pharmacology

authors： Jones RL,Mo G,Baldwin JR,Peterson PM,Ilaria RL Jr,Conti I,Cronier DM,Tap WD

更新日期：2019-01-01 00:00:00

abstract：PURPOSE:Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies. The purpose of this study was to assess the efficacy of a combination of docetaxel, capecitabine, and cisplatin (TXP) in patients diagnosed w...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu YS,Chen DR,Tseng LM,Yeh DC,Chen ST,Hsieh CM,Wang HC,Yeh HT,Kuo SH,Huang CS

更新日期：2011-06-01 00:00:00

abstract：:We obtained evidence that the cytotoxic effect of 5-fluorouracil (5-FU) is augmented when the drug is given in combination with hyperthermia (HYP) and dipyridamole (DP). Nontoxic levels of DP enhanced the combined cytotoxicity of 5-FU and HYP against B16 melanoma and human tumor cells in vitro as measured by the succi...

journal_title：Cancer chemotherapy and pharmacology

authors： Maehara Y,Sakaguchi Y,Takahashi I,Yoshida M,Kusumoto H,Masuda H,Sugimachi K

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:To investigate whether coadministration of vindesine is a risk factor for acute kidney injury caused by high-dose methotrexate in patients with hematologic malignancies and identify its mechanism. METHODS:A retrospective analysis was conducted on 211 cycles of HD-MTX therapy in 178 patients with hematological ...

journal_title：Cancer chemotherapy and pharmacology

authors： Huang C,Xia F,Xue L,Liu L,Bian Y,Jin Z,Miao L

更新日期：2020-02-01 00:00:00

abstract：PURPOSE:Anti-angiogenic agents combined with histone deacetylase inhibitors act synergistically in vitro and in vivo. We conducted a phase I study of the combination of the anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. METHODS:Bevacizumab w...

journal_title：Cancer chemotherapy and pharmacology

authors： Wheler JJ,Janku F,Falchook GS,Jackson TL,Fu S,Naing A,Tsimberidou AM,Moulder SL,Hong DS,Yang H,Piha-Paul SA,Atkins JT,Garcia-Manero G,Kurzrock R

更新日期：2014-03-01 00:00:00

abstract：:A total of 40 patients with metastatic breast cancer were treated with 120 mg/m2 i.v. epirubicin every 3 weeks for a maximum of 10 cycles. Nine achieved a complete response and 17 showed a partial response, for an objective response rate of 65% (95% confidence interval, 47%-83%); the median duration of response was 7 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Carmo-Pereira J,Costa FO,Miles DW,Henriques E,Richards MA,Rubens RD

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:We investigated whether verapamil (VR), a known chemosensitizing agent of P-glycoprotein-mediated multidrug resistance, could enhance the preventative effect of doxorubicin (Adriamycin, ADM) on both intravesical recurrence and disease progression after transurethral resection (TUR) of superficial bladder cancer...

journal_title：Cancer chemotherapy and pharmacology

authors： Naito S,Kotoh S,Omoto T,Osada Y,Sagiyama K,Iguchi A,Ariyoshi A,Hiratsuka Y,Kumazawa J

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:Bevacizumab or temsirolimus regimens have clinical activity in the first-line treatment of advanced renal cell carcinoma (RCC). This phase I/II trial was conducted to determine the safety of combining both agents and its efficacy in RCC patients who progressed on at least one prior anti-VEGF receptor tyrosine k...

journal_title：Cancer chemotherapy and pharmacology

authors： Merchan JR,Qin R,Pitot H,Picus J,Liu G,Fitch T,Maples WJ,Flynn PJ,Fruth BF,Erlichman C

更新日期：2015-03-01 00:00:00

abstract：PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). METHODS:Patients with advanced or recurrent untreated non-squamous NSCLC received ...

journal_title：Cancer chemotherapy and pharmacology

authors： Koba T,Minami S,Nishijima-Futami Y,Masuhiro K,Kimura H,Futami S,Yaga M,Mori M,Kagawa H,Uenami T,Kohmo S,Otsuka T,Yamamoto S,Komuta K,Kijima T

更新日期：2018-07-01 00:00:00

abstract：:Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation. First, eligible patients were divided into two groups (solitary and multiple) and then t...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsushima T,Matsumura Y,Ozaki Y,Yoshimoto J,Ohmori H

更新日期：1987-01-01 00:00:00

abstract：:DDMP, a diaminopyrimidine folate antagonist, was given to 26 tumor patients in a dosage of 50 mg/m2 per week orally, simultaneously with 3 mg CF i.m. or i.v. The CF dose was increased to 30 mg in patients showing evidence of toxicity, and withdrawn in the absence of toxicity. The dose-limiting toxicity was seen in mye...

journal_title：Cancer chemotherapy and pharmacology

authors： Alberto P,Peytremann R,Medenica R,Beretta-Piccoli M

更新日期：1978-01-01 00:00:00

abstract：:Axitinib is approved with indication in patients with advanced renal cell carcinoma (RCC). Due to the localization of this cancer, physicians sometimes have to deal with hemodialyzed patients. Data exploring hemodialysis (HD) impact on axitinib pharmacokinetic (PK) or safety are lacking. To date, no data have been pub...

journal_title：Cancer chemotherapy and pharmacology

authors： Thiery-Vuillemin A,Orillard E,Mouillet G,Calcagno F,Devillard N,Bouchet S,Royer B

更新日期：2017-06-01 00:00:00

abstract：PURPOSE:We report the unexpected absence of early relapse (before 30 months) in 24 consecutive patients with isolated limb primary Ewing sarcoma treated with an intensified pilot protocol, SCMCIE94. METHODS:Clinical data for the study were collected retrospectively from the patient files. The protocol included 6 cours...

journal_title：Cancer chemotherapy and pharmacology

authors： Cohen IJ,Toledano H,Stein J,Kollender Y,Fenig E,Konen O,Bar-Sever Z,Issakov J,Feinmesser M,Avigad S,Ash S

更新日期：2019-05-01 00:00:00

abstract：PURPOSE:Thalidomide has recently shown significant promise in the treatment of some types of cancer, and trials in combination with conventional chemotherapy are being undertaken. We wished to determine whether thalidomide potentiated the effect of cyclophosphamide, a commonly used cytotoxic drug, in a murine tumour mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Ding Q,Kestell P,Baguley BC,Palmer BD,Paxton JW,Muller G,Ching LM

更新日期：2002-09-01 00:00:00

abstract：PURPOSE:Hypoxic tumor cells overexpressing hypoxia-inducible factor 1alpha (HIF-1alpha) are generally resistant to chemo/radiotherapy. We have reported that Se-methylselenocysteine (MSC) therapeutically enhances the efficacy and selectivity of irinotecan against human tumor xenografts. The aim of this study was to deli...

journal_title：Cancer chemotherapy and pharmacology

authors： Chintala S,Tóth K,Cao S,Durrani FA,Vaughan MM,Jensen RL,Rustum YM

更新日期：2010-10-01 00:00:00

abstract：BACKGROUND:Rapidly dividing tumor cells have an increased demand for nutrients to support their characteristic unabated growth; this demand is met by an increased availability of nutrients such as amino acids through vasculogenesis and by the enhanced cellular entry of nutrients through the upregulation of specific tra...

journal_title：Cancer chemotherapy and pharmacology

authors： Trojel-Hansen C,Erichsen KD,Christensen MK,Jensen PB,Sehested M,Nielsen SJ

更新日期：2011-07-01 00:00:00

abstract：PURPOSE:Based on the preclinical evidence of topoisomerase I (Topo-1) upregulation by mitomycin C(MMC) and decreased NF-kappaB activation by celecoxib, we evaluated combinations of irinotecan/MMC and irinotecan/MMC/celecoxib in patients with advanced solid malignancies. PATIENTS-METHODS:Initially, patients received MM...

journal_title：Cancer chemotherapy and pharmacology

authors： Xu Y,Kolesar JM,Schaaf LJ,Drengler R,Duan W,Otterson G,Shapiro C,Kuhn J,Villalona-Calero MA

更新日期：2009-05-01 00:00:00

abstract：PURPOSE:The combination of capecitabine and paclitaxel (XP) has demonstrated synergistic antitumor activity in preclinical models. The purpose of this phase II study was to evaluate the efficacy and safety of a monthly XP regimen in patients with metastatic breast cancer (MBC). METHODS:Eligible patients had received o...

journal_title：Cancer chemotherapy and pharmacology

authors： Taguchi T,Yamamoto D,Masuda N,Oba K,Nakayama T,Nagata T,Nomura M,Yoshidome K,Yoshino H,Matsunami N,Miyashita M,Furuya Y,Ishida T,Wakita K,Sakamoto J,Noguchi S,Kinki Breast Cancer Study Group (KBCSG).

更新日期：2013-03-01 00:00:00

abstract：PURPOSE:Based on our mouse xenograft model demonstrating that intermittent high-dose gefitinib sensitizes tumors to subsequent treatment with taxanes, we initiated this phase I trial to explore docetaxel in combination with escalating doses of intermittent gefitinib (Iressa) given prior to docetaxel. METHODS:This was ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fury MG,Solit DB,Su YB,Rosen N,Sirotnak FM,Smith RP,Azzoli CG,Gomez JE,Miller VA,Kris MG,Pizzo BA,Henry R,Pfister DG,Rizvi NA

更新日期：2007-03-01 00:00:00

abstract：PURPOSE:The potential use of combined therapy is under intensive study including the association between classical cytotoxic and genes encoding toxic proteins which enhanced the antitumour activity. The main aim of this work was to evaluate whether the gef gene, a suicide gene which has a demonstrated antiproliferative...

journal_title：Cancer chemotherapy and pharmacology

authors： Prados J,Melguizo C,Rama AR,Ortiz R,Segura A,Boulaiz H,Vélez C,Caba O,Ramos JL,Aránega A

更新日期：2010-05-01 00:00:00

abstract：:Purified human leukocyte interferon produced by recombinant techniques (IFN-alpha A) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents a...

journal_title：Cancer chemotherapy and pharmacology

authors： Aapro MS,Alberts DS,Salmon SE

更新日期：1983-01-01 00:00:00

abstract：BACKGROUND:Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy. In vitro, aprepitant is a moderate inhibitor of the CYP3A4 enzyme, which is involved in the clearance of several chemotherapeutic agents. In this st...

journal_title：Cancer chemotherapy and pharmacology

authors： Nygren P,Hande K,Petty KJ,Fedgchin M,van Dyck K,Majumdar A,Panebianco D,de Smet M,Ahmed T,Murphy MG,Gottesdiener KM,Cocquyt V,van Belle S

更新日期：2005-06-01 00:00:00

abstract：:PSC-833, a non immunosuppressive analogue of cyclosporin A, is an effective modulator of the multidrug-resistant tumor phenotype. Since both PSC-833 and cyclosporin A also enhance the cytotoxicity of VP-16 against drug sensitive L1210 leukemia cells in vitro we compared these agents as modulators of VP-16 efficacy in ...

journal_title：Cancer chemotherapy and pharmacology

authors： Slater LM,Sweet P,Stupecky M,Osann K

更新日期：1997-01-01 00:00:00

abstract：:The ability of the polysulfonated antitumor drug suramin and six related polysulfonated azo dyes to inhibit the cell growth, platelet-derived growth factor (PDGF)-receptor binding, and intracellular Ca2+ signaling of Swiss 3T3 fibroblasts was studied. Some of the azo dyes were more potent inhibitors of PDGF binding th...

journal_title：Cancer chemotherapy and pharmacology

authors： Powis G,Seewald MJ,Melder D,Hoke M,Gratas C,Christensen TA,Chapman DE

更新日期：1992-01-01 00:00:00

abstract：:We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines. DDH belongs to a family of aldoketo reductases that are involved in the detoxifica...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen J,Adikari M,Pallai R,Parekh HK,Simpkins H

更新日期：2008-05-01 00:00:00

abstract：PURPOSE:To investigate any effect of a CYP3A4 inhibitor (ketoconazole) or inducer (rifampicin) on cediranib steady-state pharmacokinetics in patients with advanced solid tumours. METHODS:In two Phase I, open-label trials, patients received once-daily oral doses of cediranib alone [20 mg (ketoconazole study); 45 mg (ri...

journal_title：Cancer chemotherapy and pharmacology

authors： Lassen U,Miller WH,Hotte S,Evans TR,Kollmansberger C,Adamson D,Nielsen DL,Spicer J,Chen E,Meyer T,Brown K,Rafi R,Sawyer MB

更新日期：2013-02-01 00:00:00